Paxman Q3 (Initial take): Softer sales but better costs than expected - Redeye

Redeye provides an initial take following Paxman’s Q3 2025 report. The report was somewhat softer than anticipated, but we see no cause for concern. We continue to view 2025 as a transitional year ahead of a more eventful 2026. We will publish a research update shortly, where we expect to make modest downward revisions to our sales forecast. This will likely have a minor negative effect on our fair value range, although no material change is expected.

Länk till analysen i sin helhet: https://www.redeye.se/research/1139017/paxman-q3-initial-take-softer-sales-but-better-costs-than-expected?utm_source=finwire&utm_medium=RSS